Gregory Simpson, MD
Basic profileGregory Simpson is a Dermatology physician affiliated with University of California System. OpenAlex indexes 16 publications with 330 citations (h-index 6); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD
Sponsor: Think Now Incorporated
- Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)
Sponsor: Think Now Incorporated
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JanssenProgram year202513 paymentsResearch$51,421
- AbbVieProgram year20251 paymentResearch$1,720
- Laborie Medical Technologies Corp.Program year20251 payment$46
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
37.1%Corticosteroid26.1%Triamcinolone Acetonide51%Triamcinolone acetonide45%Halobetasol Propionate4%Part D + Part B<11 patientsInterleukin-4 Receptor alpha Antagonist7.1%Dupixent Pen50%Dupixent Syringe50%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
24.3%TNF inhibitor6.3%Humira(Cf) Pen82%Humira(Cf)18%Part D<11 patientsFolate Analog Metabolic Inhibitor5.2%Methotrexate100%Part D<11 patients+ 5 more classes in this area
Anti-infectives
12.6%Azole Antifungal9.7%Ketoconazole100%Part D≥54 patientsTetracycline-class Drug1.5%Doxycycline Hyclate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 1998–2022 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Ginsberg, MD
University of California System
Mark Mannis, MD
University of California System
Lori Daniels, MD
University of California System
Jon Davids, MD
University of California System
Bridget Grant, MD
Bassett Medical Center
Robert Modlin, MD
University of California, Los Angeles
Andrew Blauvelt, MD
University of Maryland School of Medicine
Howard Maibach, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”